{"id":"intravenous-immune-globulin-g","safety":{"commonSideEffects":[{"rate":"5-15","effect":"Headache"},{"rate":"5-10","effect":"Fever"},{"rate":"5-10","effect":"Chills"},{"rate":"5-10","effect":"Myalgia"},{"rate":"3-8","effect":"Nausea"},{"rate":"5-15","effect":"Infusion site reactions"},{"rate":"0.1-1","effect":"Aseptic meningitis"},{"rate":"0.5-2","effect":"Thromboembolism"},{"rate":"0.5-2","effect":"Acute kidney injury"}]},"_chembl":null,"_dailymed":{"setId":"9306c5f7-ddf9-5190-d0c1-31ba9ca2d0e0","title":"PANZYGA (IMMUNE GLOBULIN INTRAVENOUS (HUMAN)) SOLUTION [OCTAPHARMA USA INC]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"IVIG is a blood product containing polyclonal IgG antibodies collected from thousands of healthy donors. It works through multiple mechanisms: providing opsonizing antibodies against pathogens, blocking pathogenic autoantibodies, modulating complement activation, and regulating T and B cell function. It is used both for immunodeficiency replacement and as an immunomodulatory agent in autoimmune and inflammatory conditions.","oneSentence":"Intravenous immune globulin G (IVIG) provides passive immunity by delivering pooled immunoglobulin G antibodies from multiple donors to boost immune function and modulate inflammatory responses.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T05:11:27.605Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Primary immunodeficiency syndromes"},{"name":"Secondary immunodeficiency (e.g., chronic lymphocytic leukemia, HIV)"},{"name":"Idiopathic thrombocytopenic purpura (ITP)"},{"name":"Chronic inflammatory demyelinating polyneuropathy (CIDP)"},{"name":"Multifocal motor neuropathy"},{"name":"Kawasaki disease"},{"name":"Post-transfusion purpura"},{"name":"Autoimmune hemolytic anemia"}]},"trialDetails":[{"nctId":"NCT05139017","phase":"PHASE2, PHASE3","title":"A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2022-01-14","conditions":"DLBCL, Diffuse Large B-Cell Lymphoma","enrollment":290},{"nctId":"NCT00092222","phase":"PHASE2","title":"Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2004-10-28","conditions":"Lymphoproliferative Disorder, HHV-8, Malignancy","enrollment":75},{"nctId":"NCT06290141","phase":"PHASE3","title":"A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)","status":"RECRUITING","sponsor":"Sanofi","startDate":"2024-08-21","conditions":"Chronic Inflammatory Demyelinating Polyneuropathy","enrollment":160},{"nctId":"NCT06717347","phase":"PHASE3","title":"A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-01-27","conditions":"Diffuse Large B-Cell Lymphoma","enrollment":1046},{"nctId":"NCT05929664","phase":"PHASE2","title":"Cemiplimab Plus Fianlimab for the Treatment of Locally Advanced Head and Neck Basal Cell Carcinoma Before Surgery","status":"RECRUITING","sponsor":"Thomas Jefferson University","startDate":"2023-07-05","conditions":"Locally Advanced Basal Cell Carcinoma, Basal Cell Carcinoma","enrollment":70},{"nctId":"NCT03288545","phase":"PHASE1, PHASE2","title":"A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer","status":"TERMINATED","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2017-10-11","conditions":"Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, Urologic Neoplasms","enrollment":348},{"nctId":"NCT06890884","phase":"PHASE2","title":"A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-04-11","conditions":"Lymphoma, Large B-Cell, Diffuse","enrollment":594},{"nctId":"NCT06649331","phase":"PHASE2","title":"Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2024-10-21","conditions":"Advanced Breast Cancer, Metastatic Breast Cancer, Triple Negative Breast Cancer (TNBC)","enrollment":160},{"nctId":"NCT06859424","phase":"PHASE2","title":"A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation","status":"RECRUITING","sponsor":"Center for International Blood and Marrow Transplant Research","startDate":"2025-07-25","conditions":"AML (Acute Myelogenous Leukemia), Acute Lymphoid Leukemia (ALL), Acute Leukemia (Category)","enrollment":358},{"nctId":"NCT06508463","phase":"PHASE1","title":"Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell Lymphoma","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2024-01-05","conditions":"Peripheral T Cell Lymphoma, Relapsed Peripheral T-Cell Lymphoma, Peripheral T-Cell Lymphoma, Not Otherwise Specified","enrollment":21},{"nctId":"NCT07299695","phase":"PHASE3","title":"Intravenous Immunoglobulin for the Treatment of Acute Exacerbations of Idiopathic Pulmonary Fibrosis","status":"RECRUITING","sponsor":"Argyrios Tzouvelekis","startDate":"2026-01-25","conditions":"Idiopathic Pulmonary Fibrosis, Acute Exacerbation of Idiopathic Pulmonary Fibrosis","enrollment":196},{"nctId":"NCT07059000","phase":"PHASE3","title":"A Study Investigating Intravenous Human Normal Immunoglobulin 10% in Adults With Chronic Immune Thrombocytopenia (ITP)","status":"RECRUITING","sponsor":"Kedrion S.p.A.","startDate":"2025-08-13","conditions":"Chronic Primary Immune Thrombocytopenia (ITP)","enrollment":40},{"nctId":"NCT06533098","phase":"PHASE3","title":"A Study of Nipocalimab or Intravenous Immunoglobulin (IVIG) in Pregnancies At Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2025-02-10","conditions":"Thrombocytopenia, Neonatal Alloimmune","enrollment":50},{"nctId":"NCT06752356","phase":"PHASE3","title":"A Study Investigating Intravenous Human Normal Immune Globulin (IGIV) 10% in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)","status":"RECRUITING","sponsor":"Kedrion S.p.A.","startDate":"2026-04","conditions":"Chronic Inflammatory Demyelinating Polyneuropathy","enrollment":161},{"nctId":"NCT06742190","phase":"PHASE3","title":"A Study to Assess the Efficacy and Safety of Empasiprubart Versus IVIg in Adults With Multifocal Motor Neuropathy","status":"RECRUITING","sponsor":"argenx","startDate":"2024-12-18","conditions":"Multifocal Motor Neuropathy (MMN), MMN","enrollment":115},{"nctId":"NCT07340463","phase":"PHASE2","title":"The Efficacy and Safety of Biologics (Belimumab/ Telitacicept) Induction Therapy in Proliferative Lupus Nephritis Patients for 6 Months Compared With Mycophenolate Mofetil Treatment","status":"RECRUITING","sponsor":"Nanjing University School of Medicine","startDate":"2025-12-08","conditions":"Systemic Lupus Erythematosus (SLE), Lupus Nephritis (LN)","enrollment":50},{"nctId":"NCT05701189","phase":"PHASE2","title":"Evaluating Efgartigimod in Patients With Guillain-Barré Syndrome","status":"WITHDRAWN","sponsor":"Chafic Karam","startDate":"2024-09-10","conditions":"Guillain-Barre Syndrome","enrollment":""},{"nctId":"NCT03876288","phase":"","title":"Gastroparesis Outcome Longitudinal Database Enrolled Numerically","status":"RECRUITING","sponsor":"University of Louisville","startDate":"2013-01-01","conditions":"Gastroparesis","enrollment":3000},{"nctId":"NCT07257419","phase":"PHASE1","title":"CD45RA-depleted CD19-CAR T Cell Consolidation After TCRαβ+/CD19 B Cell-depleted Haploidentical Hematopoietic Cell Transplantation for Relapsed/Refractory CD19+ ALL and Lymphoma","status":"RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2026-03-03","conditions":"Relapsed Pediatric ALL, Hematopoietic Cell Transplantation, Hematologic Malignancy","enrollment":60},{"nctId":"NCT04609761","phase":"PHASE2","title":"Open-label Trial of IVIG in Children With PANS","status":"COMPLETED","sponsor":"Göteborg University","startDate":"2021-01-12","conditions":"PANS Pediatric Acute-Onset Neuropsychiatric Syndrome","enrollment":17},{"nctId":"NCT06920004","phase":"PHASE3","title":"A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP","status":"RECRUITING","sponsor":"argenx","startDate":"2025-08-22","conditions":"Chronic Inflammatory Demyelinating Polyneuropathy, CIDP, CIDP - Chronic Inflammatory Demyelinating Polyneuropathy","enrollment":218},{"nctId":"NCT05350774","phase":"PHASE2","title":"Immunotherapy for Neurological Post-Acute Sequelae of SARS-CoV-2","status":"ENROLLING_BY_INVITATION","sponsor":"National Institute of Neurological Disorders and Stroke (NINDS)","startDate":"2023-07-10","conditions":"Systemic Inflammation, Neuroinflammation, Microvascular Thrombosis","enrollment":45},{"nctId":"NCT03849651","phase":"PHASE2","title":"TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2019-01-31","conditions":"Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS)","enrollment":69},{"nctId":"NCT05579366","phase":"PHASE1, PHASE2","title":"Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)","status":"RECRUITING","sponsor":"Genmab","startDate":"2022-12-07","conditions":"High Grade Epithelial Ovarian Cancer, High Grade Serous Ovarian Cancer, Primary Peritoneal Carcinoma","enrollment":764},{"nctId":"NCT06191744","phase":"PHASE3","title":"Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma","status":"RECRUITING","sponsor":"Genmab","startDate":"2024-02-05","conditions":"Follicular Lymphoma (FL)","enrollment":1095},{"nctId":"NCT05832034","phase":"PHASE2, PHASE3","title":"Add-on Intravenous Immunoglobulins in Early Myositis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","startDate":"2021-09-13","conditions":"Inflammatory Myopathy, Idiopathic, Dermatomyositis, Antisynthetase Syndrome","enrollment":44},{"nctId":"NCT04438382","phase":"PHASE2","title":"Infliximab and Intravenous Immunoglobulin Therapy in Treating Patients With Steroid-Refractory Pneumonitis","status":"TERMINATED","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2021-01-07","conditions":"Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Steroid-Refractory Pneumonitis","enrollment":1},{"nctId":"NCT05662228","phase":"PHASE2","title":"Therapies for Down Syndrome Regression Disorder","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Colorado, Denver","startDate":"2023-06-29","conditions":"Down Syndrome, Regression","enrollment":66},{"nctId":"NCT05156710","phase":"PHASE2","title":"BIVV020 (SAR445088) in Prevention and Treatment of Antibody-mediated Rejection (AMR)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi","startDate":"2022-06-09","conditions":"Transplant Rejection","enrollment":48},{"nctId":"NCT06475235","phase":"PHASE1","title":"Pembrolizumab + Chemotherapy in Newly Diagnosed PCNSL","status":"RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2024-10-18","conditions":"Lymphoma, Primary Central Nervous System Lymphoma","enrollment":15},{"nctId":"NCT06305780","phase":"PHASE2","title":"RECOVER-AUTONOMIC Platform Protocol","status":"COMPLETED","sponsor":"Kanecia Obie Zimmerman","startDate":"2024-03-11","conditions":"Long COVID, Long Covid19, Long Covid-19","enrollment":381},{"nctId":"NCT04224558","phase":"PHASE1, PHASE2","title":"Stem Cell Transplantation in Crohn's Disease","status":"RECRUITING","sponsor":"Cedars-Sinai Medical Center","startDate":"2019-11-15","conditions":"Crohn Disease","enrollment":15},{"nctId":"NCT04818177","phase":"","title":"Immunoglobulin G Therapy Dose Optimization","status":"COMPLETED","sponsor":"Rutgers, The State University of New Jersey","startDate":"2021-04-01","conditions":"Obesity, Immune Deficiency","enrollment":40},{"nctId":"NCT05171660","phase":"PHASE3","title":"Combination With Sintilimab and XELOX+Bevacizumab as 1st Line Therapy in RAS-mutant Metastatic Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2022-02-08","conditions":"Colorectal Cancer Stage IV","enrollment":446},{"nctId":"NCT06798012","phase":"PHASE2","title":"A Study of TAK-411 in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)","status":"RECRUITING","sponsor":"Takeda","startDate":"2025-05-14","conditions":"Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)","enrollment":36},{"nctId":"NCT02201576","phase":"PHASE2","title":"Bortezomib in Rejection of Kidney Transplants","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2015-02-11","conditions":"Chronic Antibody-mediated Transplant Rejection","enrollment":60},{"nctId":"NCT04449874","phase":"PHASE1","title":"A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genentech, Inc.","startDate":"2020-07-29","conditions":"Non-Small Cell Lung Cancer, Colorectal Cancer, Advanced Solid Tumors","enrollment":498},{"nctId":"NCT06366347","phase":"PHASE2","title":"ALPINE: Maintenance Letrozole/Abemaciclib","status":"RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2024-09-25","conditions":"Endometrial Cancer, Recurrent Endometrial Cancer, TP53","enrollment":32},{"nctId":"NCT05620017","phase":"PHASE1","title":"Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of BAT8008 for Injection","status":"RECRUITING","sponsor":"Bio-Thera Solutions","startDate":"2022-11-30","conditions":"Advanced Solid Tumors","enrollment":182},{"nctId":"NCT07389187","phase":"EARLY_PHASE1","title":"Safety and Preliminary Efficacy Evaluation of LC-K76 Plus Anti-PD-1 Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Changzheng Hospital","startDate":"2026-02","conditions":"mCRPC","enrollment":10},{"nctId":"NCT05755035","phase":"PHASE2, PHASE3","title":"A Study About How TAK-881 is Processed by the Body and Side Effects in People With Primary Immunodeficiency Diseases","status":"COMPLETED","sponsor":"Takeda","startDate":"2023-10-24","conditions":"Primary Immunodeficiency Diseases (PID)","enrollment":65},{"nctId":"NCT02315326","phase":"PHASE1, PHASE2","title":"Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Patients With Newly Diagnosed or Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL) and Refractory/Recurrent Secondary Central Nervous System Lymphoma (SCNSL)","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2014-12-08","conditions":"Adult Patients With Newly Diagnosed or Relapsed or Refractory Primary Central Nervous System Lymphoma (PCNSL), Or Relapsed or Refractory Secondary Central Nervous System Lymphoma (SCNSL)","enrollment":93},{"nctId":"NCT04626635","phase":"PHASE1, PHASE2","title":"A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination With Cemiplimab for Adult Participants With Advanced Cancers","status":"RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2020-12-21","conditions":"Advanced Solid Tumors","enrollment":933},{"nctId":"NCT06925360","phase":"PHASE2","title":"IVIG Trial for the Treatment of Bronchopulmonary Dysplasia","status":"RECRUITING","sponsor":"International Peace Maternity and Child Health Hospital","startDate":"2025-04-12","conditions":"Bronchopulmonary Dysplasia","enrollment":20},{"nctId":"NCT05174637","phase":"PHASE1","title":"A Study of FDA018-ADC in Patients With Advanced Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.","startDate":"2021-10-22","conditions":"Advanced/ Metastatic Solid Tumors","enrollment":78},{"nctId":"NCT06445075","phase":"PHASE2","title":"Efficacy and Safety of Apitegromab for the Treatment of Adults Who Are Overweight or Obese","status":"COMPLETED","sponsor":"Scholar Rock, Inc.","startDate":"2024-05-21","conditions":"Overweight and Obesity","enrollment":102},{"nctId":"NCT06962631","phase":"PHASE3","title":"V-IMMUNE® for Immune Thrombocytopenia","status":"RECRUITING","sponsor":"On Pharma Importadora, Exportadora e Distribuidora de Medicamentos LTDA.","startDate":"2025-07-18","conditions":"Immune Thrombocytopenia (ITP)","enrollment":31},{"nctId":"NCT06954441","phase":"PHASE3","title":"V-IMMUNE: A Novel Immunoglobulin Therapy for Immunodeficiency","status":"RECRUITING","sponsor":"On Pharma Importadora, Exportadora e Distribuidora de Medicamentos LTDA.","startDate":"2025-08-15","conditions":"Immunodeficiencies, Primary Immunodeficiencies (PID), Agammaglobulinemia","enrollment":50},{"nctId":"NCT02807103","phase":"PHASE3","title":"Rituximab in Eosinophilic Granulomatosis With Polyangiitis","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2016-12-05","conditions":"Eosinophilic Granulomatosis With Polyangiitis (EGPA)","enrollment":107},{"nctId":"NCT05183035","phase":"PHASE3","title":"Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)","status":"RECRUITING","sponsor":"PedAL BCU, LLC","startDate":"2022-10-01","conditions":"Acute Myeloid Leukemia","enrollment":98},{"nctId":"NCT06351332","phase":"PHASE1, PHASE2","title":"ZAP-IT: ZN-c3 + Carboplatin + Pembrolizumab in mTNBC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Filipa Lynce, MD","startDate":"2024-05-01","conditions":"Breast Cancer, Breast Cancer Female, Triple Negative Breast Cancer","enrollment":78},{"nctId":"NCT01917721","phase":"PHASE2","title":"Doxycycline Treatment to Prevent Progressive Coronary Artery Dilation in Children With Kawasaki Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hawaii Pacific Health","startDate":"2013-10","conditions":"Kawasaki Disease, Coronary Aneurysm","enrollment":50},{"nctId":"NCT07094048","phase":"PHASE4","title":"Immunoglobulins in Multiple Myeloma Patients Receiving a BCMA-Directed T Cell Engager","status":"RECRUITING","sponsor":"CHU de Quebec-Universite Laval","startDate":"2026-01-05","conditions":"Multiple Myeloma Refractory, Relapsed Multiple Myeloma","enrollment":80},{"nctId":"NCT01596335","phase":"PHASE3","title":"Clinical Study of TA-650 in Patients With Refractory Kawasaki Disease","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2012-05","conditions":"Kawasaki Disease Refractory to Initial Therapy With Intravenous Immunoglobulin","enrollment":31},{"nctId":"NCT04078568","phase":"PHASE3","title":"Efficacy of Immunoglobulin Plus Prednisolone in Reducing Coronary Artery Lesion in Patients With Kawasaki Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Hospital of Fudan University","startDate":"2020-01-15","conditions":"Kawasaki Disease","enrollment":3208},{"nctId":"NCT01757418","phase":"PHASE1, PHASE2","title":"Intravenous Gammaglobulin for Sickle Cell Pain Crises","status":"COMPLETED","sponsor":"Albert Einstein College of Medicine","startDate":"2008-11","conditions":"Sickle Cell Disease, Pain","enrollment":300},{"nctId":"NCT07233213","phase":"PHASE3","title":"An Open-label Study of Intravenous Immunoglobulin (5%) for the Treatment of Primary Immune Thrombocytopenia","status":"RECRUITING","sponsor":"Grand Shuyang Life Sciences (Chengdu) Co., Ltd.","startDate":"2025-11-24","conditions":"Primary Immune Thrombocytopenia (ITP)","enrollment":36},{"nctId":"NCT06015750","phase":"PHASE4","title":"Mitigate Immune-Mediated Loss of Therapeutic Response to Asfotase Alfa (STRENSIQ®) for Hypophosphatasia","status":"WITHDRAWN","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2026-07-29","conditions":"Hypophosphatasia","enrollment":""},{"nctId":"NCT03281369","phase":"PHASE1, PHASE2","title":"A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2017-10-13","conditions":"Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma","enrollment":214},{"nctId":"NCT04009681","phase":"PHASE1, PHASE2","title":"A Study Evaluating Safety and Therapeutic Activity of THOR-707 in Adult Subjects With Advanced or Metastatic Solid Tumors (THOR-707-101)","status":"TERMINATED","sponsor":"Synthorx, Inc, a Sanofi company","startDate":"2019-06-20","conditions":"Metastasis","enrollment":175},{"nctId":"NCT05584631","phase":"PHASE1","title":"IVIG vs SCIG in CIDP","status":"RECRUITING","sponsor":"Rutgers, The State University of New Jersey","startDate":"2022-09-11","conditions":"CIDP, Immunoglobulin Deficiency, Chronic Inflammatory Demyelinating Polyneuropathy","enrollment":20},{"nctId":"NCT01046825","phase":"PHASE2, PHASE3","title":"Mature B-Cell Lymphoma And Leukemia Study III","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2010-09-09","conditions":"Mature B-Cell Lymphoma","enrollment":128},{"nctId":"NCT05494593","phase":"PHASE4","title":"A Study of ELAPRASE in Treatment-naïve Participants With Hunter Syndrome (Mucopolysaccharidosis [MPS] II)","status":"WITHDRAWN","sponsor":"Takeda","startDate":"2023-02-28","conditions":"Mucopolysaccharidosis (MPS), Hunter Syndrome","enrollment":""},{"nctId":"NCT02176863","phase":"PHASE2, PHASE3","title":"Study of the Efficacy and Safety of Immune Globulin Intravenous (Human) Flebogamma® 5% Dual Inactivation and Filtration (DIF) in Participants With Post-polio Syndrome","status":"TERMINATED","sponsor":"Instituto Grifols, S.A.","startDate":"2014-09-23","conditions":"Post-polio Syndrome","enrollment":191},{"nctId":"NCT05084053","phase":"PHASE3","title":"A Study of TAK-771 in Japanese Participants With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) and Multifocal Motor Neuropathy (MMN)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Takeda","startDate":"2022-01-19","conditions":"Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP), Multifocal Motor Neuropathy (MMN)","enrollment":26},{"nctId":"NCT03307785","phase":"PHASE1","title":"Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042","status":"COMPLETED","sponsor":"Tesaro, Inc.","startDate":"2017-10-12","conditions":"Neoplasms, Metastatic Cancer, Advanced Cancer","enrollment":60},{"nctId":"NCT04701034","phase":"PHASE2","title":"Intravenous Immunoglobulin and Prednisolone for RPL After ART.","status":"COMPLETED","sponsor":"Aalborg University Hospital","startDate":"2021-01-28","conditions":"Habitual Abortion, Recurrent Pregnancy Loss, Fertility Disorders","enrollment":80},{"nctId":"NCT05513586","phase":"PHASE3","title":"A Study to Evaluate the Long-term Safety of TAK-771 in Japanese Primary Immunodeficiency Disease (PID) Participants","status":"COMPLETED","sponsor":"Takeda","startDate":"2022-09-13","conditions":"Primary Immunodeficiency Diseases (PID)","enrollment":15},{"nctId":"NCT05434234","phase":"PHASE1, PHASE2","title":"A Study of YL201 in Patients With Advanced Solid Tumors","status":"RECRUITING","sponsor":"MediLink Therapeutics (Suzhou) Co., Ltd.","startDate":"2022-05-25","conditions":"Advanced Solid Tumor","enrollment":312},{"nctId":"NCT04374877","phase":"PHASE1","title":"Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors","status":"COMPLETED","sponsor":"Coherus Oncology, Inc.","startDate":"2020-04-22","conditions":"Advanced Solid Tumor, Clear Cell Renal Cell Carcinoma, Hepatocellular Carcinoma","enrollment":145},{"nctId":"NCT06935266","phase":"PHASE1","title":"A Study of TAK-881 With and Without Ramp-Up Dosing in Healthy Adults","status":"COMPLETED","sponsor":"Takeda","startDate":"2025-04-22","conditions":"Healthy Volunteers","enrollment":64},{"nctId":"NCT05684692","phase":"PHASE2","title":"Screening Trial for Pain Relief in Schwannomatosis (STARFISH)","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2023-08-31","conditions":"Schwannomatosis, Schwannomas, Pain, Chronic","enrollment":40},{"nctId":"NCT06533826","phase":"PHASE2","title":"TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd","status":"RECRUITING","sponsor":"Ana C Garrido-Castro, MD","startDate":"2024-10-29","conditions":"Breast Cancer, HER2-low Breast Cancer, Metastatic Breast Cancer","enrollment":357},{"nctId":"NCT03684018","phase":"PHASE4","title":"Two Dose Levels of Privigen in Pediatric CIDP","status":"RECRUITING","sponsor":"CSL Behring","startDate":"2019-02-28","conditions":"Pediatric Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)","enrollment":30},{"nctId":"NCT03630211","phase":"PHASE2","title":"Autologous Stem Cell Transplantation in Patients With Systemic Sclerosis","status":"RECRUITING","sponsor":"Paul Szabolcs","startDate":"2018-07-31","conditions":"Systemic Sclerosis, Diffuse Sclerosis Systemic, Interstitial Lung Disease","enrollment":8},{"nctId":"NCT07215923","phase":"PHASE1","title":"A First in Human Single Ascending Dose (SAD) Study of ATI-1013 in Healthy Smokers","status":"RECRUITING","sponsor":"Antidote Therapeutics, Inc","startDate":"2025-10","conditions":"Thromboangiitis Obliterans (Buerger's Disease)","enrollment":15},{"nctId":"NCT07202091","phase":"PHASE2, PHASE3","title":"Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Immunoglobulin Stopping or Extension (Stop Ig)","status":"RECRUITING","sponsor":"Monash University","startDate":"2025-05-06","conditions":"Myeloma, Leukemia, Non Hodgkin's Lymphoma","enrollment":900},{"nctId":"NCT07202052","phase":"PHASE2, PHASE3","title":"Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Platform Trial (RATIONAL-PT)","status":"RECRUITING","sponsor":"Monash University","startDate":"2025-05-06","conditions":"Myeloma, Non-Hodgkin's Lymphoma, Leukemia","enrollment":900},{"nctId":"NCT07202065","phase":"PHASE2, PHASE3","title":"Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Dosing Immunoglobulin (Dose Ig)","status":"RECRUITING","sponsor":"Monash University","startDate":"2025-04-28","conditions":"Myeloma, Non Hodgkin's Lymphoma, Leukemia","enrollment":900},{"nctId":"NCT04607772","phase":"PHASE1, PHASE2","title":"Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)","status":"WITHDRAWN","sponsor":"Karyopharm Therapeutics Inc","startDate":"2020-11-18","conditions":"Relapsed or Refractory Diffuse Large B-Cell Lymphoma","enrollment":""},{"nctId":"NCT07193953","phase":"PHASE1","title":"Intravenous Immunoglobulin (IVIG) and Blood-Brain Barrier Disruption in Amyotrophic Lateral Sclerosis (ALS)","status":"RECRUITING","sponsor":"Sunnybrook Health Sciences Centre","startDate":"2025-04-15","conditions":"Amyotrophic Lateral Sclerosis, ALS","enrollment":6},{"nctId":"NCT06753955","phase":"PHASE1","title":"Phase 1 Study of ART5803 Safety and PK After IVIG in Healthy Participants","status":"ACTIVE_NOT_RECRUITING","sponsor":"Arialys Therapeutics","startDate":"2025-03-18","conditions":"Autoimmune Encephalitis Caused by N-Methyl D-Aspartate Receptor Antibody, Autoimmune Encephalitis Caused by N-Methyl D-Aspartate Receptor Antibody (Disorder), Autoimmune Encephalitis","enrollment":6},{"nctId":"NCT05698147","phase":"PHASE1, PHASE2","title":"Selinexor in Combination With MTX+Ritu to Treat R/R CNSL","status":"RECRUITING","sponsor":"Tong Chen, MD","startDate":"2023-08-03","conditions":"Central Nervous System Lymphoma","enrollment":30},{"nctId":"NCT02219165","phase":"PHASE2","title":"Efficacy of IntraVenous ImmunoGlobulins in Toxic Shock Syndromes: a Paediatric Pilot Study","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2015-01-08","conditions":"Toxic Shock Syndrome","enrollment":30},{"nctId":"NCT03646123","phase":"PHASE2","title":"Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma","status":"TERMINATED","sponsor":"Seagen Inc.","startDate":"2019-01-28","conditions":"Hodgkin Lymphoma","enrollment":255},{"nctId":"NCT04047862","phase":"PHASE1","title":"Study of Ociperlimab (BGB-A1217) in Combination With Tislelizumab in Advanced Solid Tumors","status":"COMPLETED","sponsor":"BeiGene","startDate":"2019-08-15","conditions":"Locally Advanced and Metastatic Solid Tumors","enrollment":446},{"nctId":"NCT06488378","phase":"PHASE1","title":"Phase Ib Study of Axatilimab in Combination With Olaparib in BRCA1/2 and PALB2- Associated Metastatic HER2-negative Breast Cancer","status":"RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2024-08-13","conditions":"Breast Cancer, PALB2-Mutated Breast Carcinoma, HER2-negative Breast Cancer","enrollment":20},{"nctId":"NCT06895967","phase":"PHASE1","title":"A Study of TAK-881 and HyQvia in Healthy Adults","status":"COMPLETED","sponsor":"Takeda","startDate":"2025-03-24","conditions":"Healthy Volunteers","enrollment":30},{"nctId":"NCT05583071","phase":"PHASE2","title":"Methotrexate, Tafasitamab, Lenalidomide and Rituximab in Patients With PCNSL","status":"RECRUITING","sponsor":"University of Cologne","startDate":"2024-08-23","conditions":"Non-Hodgkin Lymphoma","enrollment":20},{"nctId":"NCT02790515","phase":"PHASE2","title":"Provision of TCRγδ T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2016-07-14","conditions":"Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Myeloid Sarcoma","enrollment":170},{"nctId":"NCT03700138","phase":"PHASE3","title":"Intravenous Immunoglobulins for the Treatment of Primary Sjögren's Syndrome Associated Painful Sensory Neuropathies","status":"COMPLETED","sponsor":"University Hospital, Strasbourg, France","startDate":"2019-06-19","conditions":"Primary Sjögren's Syndrome Painful Sensory Neuropathies","enrollment":24},{"nctId":"NCT07108530","phase":"PHASE2","title":"Efficacy of Integrated Induction-Consolidation Chemotherapy and Transplantation for Adult Acute Myeloid Leukemia: Multicenter Study","status":"RECRUITING","sponsor":"Shanxi Bethune Hospital","startDate":"2025-08-06","conditions":"Acute Myeloid Leukemia","enrollment":50},{"nctId":"NCT04222023","phase":"PHASE4","title":"Intravenous Immunoglobulins for Prevention of BKV Infection in Kidney Transplant Recipients According to BKV Genotype-specific Neutralizing Antibody Titers at the Day of Transplantation.","status":"COMPLETED","sponsor":"University Hospital, Strasbourg, France","startDate":"2022-08-21","conditions":"Kidney Transplantation","enrollment":359},{"nctId":"NCT03872947","phase":"PHASE1","title":"A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Toray Industries, Inc","startDate":"2019-04-26","conditions":"Solid Tumor, Colorectal Cancer, Cholangiocarcinoma","enrollment":138},{"nctId":"NCT03939637","phase":"PHASE3","title":"Eltrombopag vs Standard Front Line Management for Newly Diagnosed Immune Thrombocytopenia (ITP) in Children","status":"COMPLETED","sponsor":"Baylor College of Medicine","startDate":"2019-05-02","conditions":"Immune Thrombocytopenia","enrollment":122},{"nctId":"NCT05735717","phase":"PHASE2","title":"MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies","status":"RECRUITING","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2023-05-11","conditions":"Hematologic Malignancy, Acute Leukemia, Remission","enrollment":70},{"nctId":"NCT06305793","phase":"PHASE2","title":"RECOVER-AUTONOMIC: Platform Protocol, Appendix A (IVIG)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Kanecia Obie Zimmerman","startDate":"2024-03-11","conditions":"Long COVID, Long Coronavirus Disease 2019 (Covid19), Long Covid-19","enrollment":200},{"nctId":"NCT07068126","phase":"NA","title":"Management of Children With Persistent ITP, A Novel Approach","status":"RECRUITING","sponsor":"Assiut University","startDate":"2025-01-01","conditions":"Persistent Immune Thrombocytopenia","enrollment":20},{"nctId":"NCT04935177","phase":"PHASE3","title":"Renal Function in Highly Sensitized Patients 1 Year After Desensitization With Imlifidase Prior to DD Kidney Tx","status":"COMPLETED","sponsor":"Hansa Biopharma AB","startDate":"2021-10-14","conditions":"Kidney Transplantation in Highly Sensitized Patients","enrollment":64},{"nctId":"NCT04400994","phase":"PHASE2","title":"IVIG With Rituximab vs Rituximab as First Line Treatment of Pemphigus","status":"ACTIVE_NOT_RECRUITING","sponsor":"The University of Hong Kong","startDate":"2020-06-20","conditions":"Pemphigus","enrollment":20}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":8,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Privigen, IVIG"],"phase":"marketed","status":"active","brandName":"Intravenous immune globulin G","genericName":"Intravenous immune globulin G","companyName":"Rutgers, The State University of New Jersey","companyId":"rutgers-the-state-university-of-new-jersey","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Intravenous immune globulin G (IVIG) provides passive immunity by delivering pooled immunoglobulin G antibodies from multiple donors to boost immune function and modulate inflammatory responses. Used for Primary immunodeficiency syndromes, Secondary immunodeficiency (e.g., chronic lymphocytic leukemia, HIV), Idiopathic thrombocytopenic purpura (ITP).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}